Open Orphan signs new deal with New York-based Codagenix for the phase I trial of new Covid-19 vaccine

Dublin-listed pharmaceutical services company Open Orphan has signed a new deal with New York-based Codagenix for the phase one trial of a new Covid-19 vaccine.

The trial, which will evaluate the safety and ability of the vaccine to evoke a repulsions in the immune system, will look at 48 healthy young adult volunteers.

The vaccine is a single-dose, intranasal candidate, and will be trialled at Open Orphan subsidiary Hvivo’s quarantine facility in Whitechapel in London. The trial will begin in early autumn, with initial data expected by the end of the year.

Open Orphan (LON:ORPH) was founded in 2017, with the goal of rapidly building Europe’s leading pharma services company by a management team with extensive industry and financial expertise. The company comprises of two commercial specialist CRO services businesses (Venn Life Sciences and hVIVO) and is also developing a genomics data platform business (Genomic Health Data). 

Click to view all articles for the EPIC:
Or click to view the full company profile:
Share on facebook
Facebook
Share on twitter
Twitter
Share on linkedin
LinkedIn
Open Orphan PLC

More articles like this

Open Orphan Plc

Open Orphan pharmaceutical company expands Covid-19 trial

Pharmaceutical services company Open Orphan is expanding its Covid-19 challenge study, inoculating up to 20 further volunteers. The government-funded trial, which is being carried out with subsidiary hVivo, involves deliberately infecting people with Covid in a controlled setting to see

Open Orphan Plc

Open Orphan subsidiary signs contract for antiviral study

Clinical research organisation (CRO) Open Orphan has announced that its subsidiary hVIVO has signed a contract with AIM ImmunoTech to test its antiviral candidate, Ampligen, against the human Rhinovirus HRV, or common cold, and influenza, in a single

Open Orphan Plc

Open Orphan signs significant contract with AIM IT to test Ampligen

Open Orphan plc (LON:ORPH), a rapidly growing specialist pharmaceutical services clinical research organisation (CRO) and world leader in vaccine and antiviral testing using human challenge clinical trials, has announced that hVIVO, a subsidiary of Open Orphan plc, has signed

Open Orphan Plc

Don’t be afraid of the FDA

The Food and Drug Administration (FDA) is an agency within the U.S. Department of Health and Human Services. It is the US Agency responsible for the regulation of drugs and biologics, including, vaccines for humans, blood and blood

Open Orphan Plc

Open Orphan launches infectious disease spinout

Clinical research organisation (CRO) Open Orphan has launched a spin-out organisation targeting the infectious disease market. Biotech Poolbeg Pharma has been created in the wake of the Covid-19 pandemic and builds upon Open Orphan’s experience and knowledge of

Open Orphan Plc

Open Orphan on Covid-19 and studying the virus

The MedTalk’s Reece Armstrong speaks to Cathal Friel, chairman and co-founder of Open Orphan, about the company’s involvement in setting up the first human challenge study model for Covid-19 and the importance of studying the virus during the